Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 9:2022:5180193.
doi: 10.1155/2022/5180193. eCollection 2022.

Efficacy of Acupuncture for Parkinson's Disease Anxiety: Two-Stage Protocol for a Randomized Controlled Clinical Trial

Jing-Qi Fan  1 , Zi-Qiao Xu  1 , Yuan-Yuan Chen  1 , Wei-Jing Lu  1 , Xiao-Yan Xie  1 , Yu-Ting Wang  1 , Li-Xing Zhuang  2
Affiliations

Efficacy of Acupuncture for Parkinson's Disease Anxiety: Two-Stage Protocol for a Randomized Controlled Clinical Trial

Jing-Qi Fan et al. Evid Based Complement Alternat Med. .

Abstract

Parkinson's disease anxiety (PDA) is a nonmotor symptom of Parkinson's disease (PD) that is often neglected. PDA poses a far-reaching challenge to the treatment of PD. Acupuncture could be successful in the treatment of PDA. However, the evidence for this is still limited. We propose a two-stage clinical trial. In stage 1, a total of 70 volunteers with PDA will be randomly assigned to either acupuncture (manual acupuncture) or control group (sham acupuncture) in a 1 : 1 ratio. Treatments will be performed for four weeks. The change in the Hamilton Rating Scale for Anxiety (HAMA) score from baseline to week 4 and week 12 will be the primary outcome. The levels of adrenocorticotropic hormone (ACTH), cortisol (CORT), serotonin (5-HT), and corticotropin-releasing factor (CRH) in the patients' serum and the scores on the Hoehn-Yahr Rating Scale and the Unified Parkinson's Disease Rating Scale (UPDRS) will all be considered among the secondary outcomes. Participants will be followed up until week 12. In stage 2, a total of 82 volunteers with PDA will be randomly assigned to either an acupuncture (manual acupuncture) or a control group (anti-Parkinson drugs only) in a 1 : 1 ratio. HAMA score will be the primary outcome. Universality, feasibility and cost effectiveness, Hoehn-Yahr Rating Scale, UPDRS, and serological indicators will be secondary outcomes. Participants will be followed up until week 4. The statistical analysis will include all the allocated individuals. The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine's Research Ethical Committee authorized this procedure, and the trial is registered with ChiCTR2100047253.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Flowchart of stage 1 of the trial.
Figure 2
Figure 2
Selection and location of the acupoints for acupuncture.
Figure 3
Figure 3
Main structure of the sham acupuncture needle.
Figure 4
Figure 4
Acupuncture needle base.
Figure 5
Figure 5
Real needle and sham needle.
Figure 6
Figure 6
Flowchart of stage 2 of the trial.
Figure 7
Figure 7
The relationship between PD and PDA.
See this image and copyright information in PMC

References

    1. Tolosa E., Garrido A., Scholz S. W., Poewe W. Challenges in the diagnosis of Parkinson’s disease. The Lancet Neurology . 2021;20(5):385–397. doi: 10.1016/s1474-4422(21)00030-2. - DOI - PMC - PubMed
    1. Dissanayaka N. N. N. W., White E., Marsh J. D., Pachana N. A., Byrne G. J. The clinical spectrum of anxiety in Parkinson’s disease. Movement Disorders . 2014;29(8):967–975. doi: 10.1002/mds.25937. - DOI - PubMed
    1. Broen M. P. G., Narayen N. E., Kuijf M. L., Dissanayaka N. N. W., Leentjens A. F. G. Prevalence of anxiety in Parkinson’s disease: a systematic review and meta‐analysis. Movement Disorders . 2016;31(8):1125–1133. doi: 10.1002/mds.26643. - DOI - PubMed
    1. Zhu K., Van Hilten J. J., Marinus J. Onset and evolution of anxiety in Parkinson’s disease. European Journal of Neurology . 2017;24(2):404–411. doi: 10.1111/ene.13217. - DOI - PubMed
    1. Bandelow B., Lichte T., Rudolf S., Wiltink J., Beutel M. E. The German guidelines for the treatment of anxiety disorders. European Archives of Psychiatry and Clinical Neuroscience . 2015;265(5):363–373. doi: 10.1007/s00406-014-0563-z. - DOI - PubMed

LinkOut - more resources